Skip to Content

Combination treatment of AML with spleen tyrosine kinase

In this MEDtalk Philipp Sergeev, MSc, Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland, presents the results of treatment with entospletinib and lanraplenib. Lanraplenib is a next generation oral SYK inhibitor with potency and selectivity comparable to entospletinib.

Philipp Sergeev

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top